Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Flora Growth's Sloan Ratio for the quarter that ended in Mar. 2024 was -210.79%.
Warning Sign:
When sloan ratio (-204.88)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2024, Flora Growth has a Sloan Ratio of -210.79%, indicating earnings are more likely to be made up of accruals.
Flora Growth Sloan Ratio % Historical Data
The historical data trend for Flora Growth's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Flora Growth's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Flora Growth's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flora Growth's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Flora Growth's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Flora Growth's Sloan Ratio % falls into.
Flora Growth Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Flora Growth's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Flora Growth's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -44.556 (Jun. 2023 ) + 1.237 (Sep. 2023 ) + -10.107 (Dec. 2023 ) + -3.374 (Mar. 2024 ) = $-56.80 Mil.
Flora Growth's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -3.459 (Jun. 2023 ) + 0.518 (Sep. 2023 ) + -1.131 (Dec. 2023 ) + -1.34 (Mar. 2024 ) = $-5.41 Mil.
Flora Growth's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.093 (Jun. 2023 ) + -0.077 (Sep. 2023 ) + 0.038 (Dec. 2023 ) + -0.088 (Mar. 2024 ) = $-0.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flora Growth (NAS:FLGC) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Flora Growth has a Sloan Ratio of -210.79%, indicating earnings are more likely to be made up of accruals.
Flora Growth Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Flora Growth's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company operates in the United States, Germany, Colombia, the United Kingdom, and Canada. it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGC has been successfully added to your 